UCDCCC NCTN UG1 PROGRAM

项目摘要/摘要 作为唯一由NCI指定的针对内陆北加州约600万人口的癌症中心， 加州大学戴维斯分校综合癌症中心(UCDCCC)为大型和 不断增长的人口，并作为该地区专科癌症护理的第三转诊中心。为了这个 申请成为NCTN网络领先的学术参与站点，由David R Gandara博士领导，医学博士和 UCDCCC医学博士Richard K Valicenti将利用已经建立的多学科癌症团队 来自内科肿瘤学、放射肿瘤学、外科专业、分子生物学/基因组学的研究人员， 病理学、放射学、生物统计学、护理和临床研究支持，以提供临床试验专业知识， 在广泛的肿瘤类型和NCTN研究中的科学和行政领导和收益 在整个NCTN集团网络中。UCDCCC及其教职员工拥有长期和可靠的记录， 对NCI赞助的临床试验活动以及与NCI相关的指导委员会做出有影响力的贡献 和主动性。UG1的这一努力预计将扩大参与的范围和范围，包括 整合更多研究人员并为新教师和初级教师提供职业发展机会 调查人员。在NCTN的翻译和临床研究领导方面已经有了很好的记录， UCDCCC准备利用独特的机构优势作为临床试验的实验室资源 并为假说驱动的临床研究做出贡献。 基于二十多年来已经成为NCI赞助研究的临床试验“枢纽”的经验 在整个加利福尼亚州中北部，NCTN UG1计划为UCDCCC创造了额外的机会 两者都增加了主站点的收益，并通过UCDCCC将NCTN试验的访问扩展到社区 癌症护理网络和附属网站，包括大量未得到充分服务的农村和少数族裔患者 人口。总之，UCDCCC代表着一种跨学科的组织和领导结构 与临床试验计划相关联，该计划将产生影响，并确保NCTN试验的强劲收益。

PROJECT SUMMARY/ABSTRACT As the only NCI-designated cancer center for inland Northern California's approximately 6 million people, the UC Davis Comprehensive Cancer Center (UCDCCC) provides both primary cancer care to a large and growing population, and serves as the tertiary referral center for specialty cancer care for the region. For this application as a NCTN Network Lead Academic Participating Site, led by Drs. David R Gandara, MD, and Richard K Valicenti, MD, UCDCCC will leverage an already established multidisciplinary team of cancer investigators from medical oncology, radiation oncology, surgical specialties, molecular biology/genomics, pathology, radiology, biostatistics, nursing, and clinical research support to provide clinical trials expertise, scientific and administrative leadership and accrual in NCTN studies across a broad range of tumor types and throughout the NCTN group network. UCDCCC and its faculty have a long-standing and proven track record of impactful contribution to NCI-sponsored clinical trials activities, as well as to NCI-related steering committees and initiatives. This UG1 effort is anticipated to increase both the scope and reach of participation, including integrating additional researchers and providing career development opportunities for new faculty and junior investigators. With an already strong track record in translational and clinical research leadership for NCTN, UCDCCC is poised to exploit unique institutional strengths in serving as a laboratory resource for clinical trials and contributing to hypothesis-driven clinical research. Based on over two decades of already serving as the clinical trials “hub” for accrual to NCI-sponsored studies throughout North-Central California, this NCTN UG1 initiative creates a additional opportunities for UCDCCC to both increase main site accrual and to extend access to NCTN trials into the community through the UCDCCC Cancer Care Network and affiliate site, which includes substantial underserved, rural and minority patient populations. In summary, UCDCCC represents an interdisciplinary organizational and leadership structure linked to a clinical trials program that will be impactful and ensure robust accrual to NCTN trials.